IP Library Granted Patent US 7,687,528
Granted Patent B2
US 7,687,528 · App. 11/508,353 · Granted Mar 30, 2010

Pharmaceutical compositions of an AT

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,687,528
App. No.
11/508,353
Granted
Mar 30, 2010
Kind
B2
Abstract

The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) an AT 1 -receptor antagonist or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.

Claims (2)

1. A method for the inhibition of the onset of, delay of progression or treatment of diabetes and/or complications therefrom comprising administering a therapeutically effective amount of a suitable dosage form consisting essentially of the AT1-receptor antagonist, valsartan.

2. The method of claim 1 wherein the diabetes is type 2 diabetes mellitus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2011
From: NOVARTIS AG
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 026002/0790 →